Recent research in the field of neuroprotection in glaucoma has focused on the N-methyl-D-aspartate (NMDA) and the a-2 adrenergic receptor systems. Experimental findings have shown that brimonidine (BMD), a specific a-2 adrenoceptor agonist, can protect against loss in mitochondrial membrane potential during oxidative stress, and preserve anterograde axonal transport. Memantine is a selective blocker of the NMDA-type glutamatergic type ion channel. It has unique open channel blocker properties that result in a preferential inhibition of excessive (excitotoxic) neuronal activation by high levels of glutamate without interfering with the channel's normal functions. In a primate model, memantine was neuroprotective as can be seen from its effect on maintaining/ preserving RGCs. Research in Alzheimer's disease has demonstrated that memantine may increase neuronal functionality as well as being protective. Research in a primate glaucoma model shows that memantine protects neurons from shrinking in the lateral geniculate nucleus. Memantine is currently in clinical trials for glaucoma.
Introduction
Research in the field of neuroprotection in glaucoma has been focused on drugs that can either enhance neuronal survival or block compounds that may cause cell death. Selective a-2 adrenergic agonists and the N-methyl-D-aspartate (NMDA) receptor blockers are examples of pharmacological agents of the aforementioned strategies to protect retinal ganglion cells (RGCs) in glaucoma that are in clinical testing. The highlights of key findings and recent discoveries, with an emphasis on the NMDA receptor system, are provided here.
The a-2 adrenergic receptor system Adrenergic receptors mediate the biological effects of the sympathetic nervous system. To date, nine distinct a-and b-adrenergic receptor subtypes have been cloned from several species. a-Adrenergic receptors are subdivided into the a-1 and a-2 subgroups.
1, 2 The precise physiological functions and therapeutic potential of many of these receptors have not been fully elucidated. However, selective agonists for the b-2 adrenergic receptor have been developed for use in asthma therapy, and a-1 receptor antagonists are first-line medication for patients with hypertension, coronary heart disease, or chronic heart failure. So far, three distinct genes have been identified from several species that encode for the three subtypes of a-2 adrenergic receptors, a-2a, -2b, and -2c.
1 These genes have highly homologous amino-acid sequences, thus making the generation of subtype selective antibodies difficult. Mapping the location of the a-2 subtypes in the eye has been problematic. However, a new set of antibodies has been successfully made. These selective antibodies have allowed the location of the a-2 adrenergic receptors in the retina to be identified. The a-2a antibody preferentially binds to RGCs, while a-2b is much more distributed in the retina, resembling Mü ller cell staining to some extent. a-2c is almost exclusively located in the photoreceptor layer. There are multiple injuries to the RGCs and surrounding cells in glaucoma, 4 offering a wide scope of opportunities for neuroprotective therapies. The mechanisms of action of a-2 agonists and their signal transduction have generated interest, because their understanding may lead to new pharmacological targets.
Involvement of a-2 adrenergic receptors in the neuroprotective signalling pathway
The mechanisms underlying the neuroprotective signalling pathway involving a-2 adrenergic receptors are not fully elucidated. One issue is that RGCs have to be highly differentiated to express a-2 receptors. Thus, neuroprotective pathways of a-2 adrenergic receptors cannot be easily studied in RGCs. This problem was overcome by studying transfected cell lines that overexpress a-2 receptors. Using these cell lines, we were able to demonstrate biochemically and functionally that the activation of mitogen-activated protein kinase (MAPK) and Akt kinase (protein kinase B) is involved in neuroprotective signalling by selective a-2 agonists such as brimonidine (BMD) (L Wheeler et al, private communication).
Specific a-2 adrenergic receptor protection against oxidative stress has also been demonstrated at the level of the mitochondrion, which is a cellular component having a key role in RGC apoptosis. We found that a-2 agonists can send signals that help to protect the mitochondria during oxidative stress. In this study, cells overexpressing a-2 adrenoceptors were loaded with JC-1 dye, a dye that is used for monitoring the mitochondrial transmembrane potential (see R Funk's presentation). When oxidative stress was induced by exposing cells to ultraviolet light in the presence or absence of BMD, loss in mitochondrial transmembrane potential induced by the oxidative stress was prevented by BMD ( Figure 1 ).
Other studies support the hypothesis that there are signalling systems in the retina that help cells under stress. Survival factors, such as brain-derived neurotrophic factor, signal through these pathways ( Figure 2 ). Research findings suggest that a-2 agonists may be an additional, or stress induced, system that helps cells deal with localized stress (Figure 2 ).
5,6
The NMDA receptor system Numerous studies have contributed to our understanding of NMDA receptor function. 7 Under physiological conditions, the NMDA channel is blocked by magnesium ions unless activity in other classes of excitatory synaptic inputs depolarizes the neuronal membrane sufficiently to relieve this block. 8 When neurons are injured, the neuronal membrane may become chronically depolarized. Under these conditions, even normal levels of extracellular glutamate will result in excessive activation of NMDA channels and a consequent overload of intracellular Na þ and Ca 2 þ ions, which flow from the extracellular space through the open NMDA channels and into the neuronal cytoplasm. Elevated cytoplasmic levels of Na þ and Ca 2 þ ions leads to further neuronal damage and mediates the neuronal injury associated with glutamatergic excitotoxicity. given fixed concentration of memantine, the fractional block of NMDA channels will increase with increasing extracellular glutamate concentration. This results from the fact that, as the concentration of glutamate is increased, the channels will spend proportionately more time in the open state and the level of memantine block will increase. This property of open-channel blockade, in combination with other properties of binding affinity and binding kinetics, makes memantine relatively more effective to block the excessive levels of NMDA channel activity associated with pathological conditions, while having relatively less effect to block the lower levels of channel activation associated with normal physiological neurotransmission. The favourable tolerability and low drop-out rate observed in Alzheimer's disease trials using memantine treatment are consistent with these properties of NMDA channel blockade by memantine. [9] [10] [11] In an ocular hypertensive rat model, memantine, a compound which does not lower intraocular pressure (IOP), has been found to prevent the progression of RGC loss subsequent to laser-induced IOP elevation. 12 In a study of chronic ocular hypertension in the primate, histological measurements showed that, for animals with moderate elevation of IOP, oral administration of memantine was associated with an enhanced survival of RGCs in the inferior retina. 13, 14 Measurements of optic nerve head topography with confocal scanning laser tomography (HRT) showed less IOP-induced change in animals treated with memantine, as reflected in measurements of the cup and neuroretinal rim (Figure 3 ). In addition, the findings indicate that memantine treatment is safe. One of the more interesting results was obtained from recordings of the visual evoked potential (VEP). When responses from animals with severe RGC loss were compared, vehicle-treated animals had lost most of the VEP response while responses obtained from memantinetreated animals were of relatively normal amplitude. 13 Further research has focused on whether memantine increases neuronal functionality, in some way, in addition to its neuroprotective effects. A neurological study showed that memantine increases brain metabolism and effectively treats mild-to-moderate Alzheimer's disease. 9, 10 In a phase III study, patients with Alzheimer's disease were treated with memantine, up to 20 mg a day, for 24 weeks.
18 F-deoxyglucose labelling was measured in patients while they identified pictures on a monitor. A positron emission tomography (PET) scanner was used to construct a picture of metabolic activity. In the regions commonly associated with Alzheimer's disease, there was a decrease in glucose uptake in the control group, whereas a very robust uptake was noted in the memantine-treated patients. 15 Yucel et al 16 have recently been able to show that memantine protects neurons from shrinking in the lateral geniculate nucleus (LGN) in experimental glaucoma in the monkey. LGN relay neurons (layers 1, 4, and 6) were examined following parvalbumin immunolabelling. Analysis of covariance results showed significantly less neuron shrinkage in the memantine-treated group for layers 1, 4, and 6 (Po0.001, Po0.02, and Po0.04, respectively). This difference was highest in layer 1. In each of these layers, neuron numbers did not differ significantly between groups. These results show that memantine treatment was associated with prevention of neuronal atrophy in higher levels of the glaucoma-injured visual pathway and are consistent with the earlier report of functional preservation based on VEP recordings from memantine-treated monkeys with experimental glaucoma.
Conclusion
Memantine can protect at multiple levels of the visual pathway. The finding that memantine protects adult visual neurons from transsynaptic atrophy in experimental glaucoma could be of therapeutic value. Currently, memantine is being tested in an ongoing clinical trial as a treatment for glaucoma. 
